SCHEMBL1190708

SCHEMBL1190708

Cc1cc(C)cc(OC=O)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
TSHR P16473 3/20 0.46
CYP3A4 P08684 1/20 0.46
MAPK1 P28482 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
NPSR1 Q6W5P4 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.38
ERN1 O75460 2/20 0.36
TPMT P51580 1/20 0.33
TP53 P04637 1/20 0.32
ALOX15 P16050 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
SRC P12931 1/20 0.32
POLB P06746 1/20 0.32
CYP2C9 P11712 1/20 0.32
MAPT P10636 2/20 0.32
THRB P10828 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16079851 0.95 ALDH1A1 (0.41) ALDH1A1TSHRCYP3A4MAPK1TDP1
SCHEMBL17898604 0.89 ALDH1A1 (0.50) ALDH1A1TSHRCYP3A4MAPK1TDP1
SCHEMBL23457679 0.86 ALDH1A1 (0.48) ALDH1A1TSHRCYP3A4MAPK1TDP1
SCHEMBL29640516 0.86 ALDH1A1 (0.48) ALDH1A1TSHRCYP3A4MAPK1TDP1
SCHEMBL8804437 0.84 ALDH1A1 (0.48) ALDH1A1TSHRCYP3A4MAPK1TDP1
SCHEMBL97383 0.84 ALDH1A1 (0.34) ALDH1A1TSHRCYP3A4MAPK1TDP1
SCHEMBL16517864 0.81 POLB (0.38) ALDH1A1TSHRCYP3A4MAPK1TDP1
SCHEMBL18573171 0.80 ALDH1A1 (0.32) ALDH1A1
SCHEMBL10212525 0.80 TPMT (0.57) ALDH1A1SMN1; SMN2TPMTMEN1KMT2A
SCHEMBL28321763 0.80 ERN1 (0.35) ALDH1A1TSHRCYP3A4MAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109085255-B Method for analyzing and preparing 3- (N-p-toluenesulfonyl-L-alanyloxy) -5-phenylpyrrole and enantiomer thereof by using HPLC method 长春百纯和成医药科技有限公司 2021-03-12 CN claimed
CN-108693272-B Method for analyzing and preparing N- (p-toluenesulfonyl) -L-alanine and enantiomer thereof by HPLC method 吉林百纯化学科技有限公司 2021-03-12 CN claimed
EP-4387954-A1 LONG-LIVED REDOX-ACTIVE MOLECULES WITH LOW REDOX POTENTIAL President and Fellows of Harvard College (US) 2024-06-26 EP disclosed
US-20240165267-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF ARES CAPITAL CORPORATION, AS AGENT 2024-05-23 US disclosed
US-11987590-B2 Compounds that participate in cooperative binding and uses thereof Revolution Medicines, Inc. (US) 2024-05-21 US disclosed
US-20240136561-A1 ELECTRICAL REGENERATION OF ELECTROLYTES PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2024-04-25 US disclosed
EP-4351662-A1 RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY Fusion Pharmaceuticals Inc. (CA) 2024-04-17 EP disclosed
CN-117794585-A Radioimmunoconjugates and checkpoint inhibitor combination therapies 融合制药公司 2024-03-29 CN disclosed
CN-117603148-A Pharmacokinetic enhancement of difunctional chelates and uses thereof 探针技术开发及商业化中心 2024-02-27 CN disclosed
CN-117482261-A Combination therapy of radioimmunoconjugates and checkpoint inhibitors 融合制药公司 2024-02-02 CN disclosed
EP-4292156-A1 ELECTRICAL REGENERATION OF ELECTROLYTES President and Fellows of Harvard College (US) 2023-12-20 EP disclosed
EP-0605149-B1 Recording sheet JUJO PAPER CO LTD (JP) 1998-04-22 EP disclosed
US-5719272-A 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives ABBOTT LABORATORIES (US) 1998-02-17 US disclosed
WO-1997036913-A1 9-OXIMESILYL ERYTHROMYCIN A DERIVATIVES ABBOTT LABORATORIES (US) 1997-10-09 WO disclosed
WO-1997036912-A1 2'-PROTECTED 3'-DIMETHYLAMINE, 9-ETHEROXIME ERYTHROMYCIN A DERIVATIVES ABBOTT LABORATORIES (US) 1997-10-09 WO disclosed
US-5482913-A CARBONATE TYPE BLOCKED COLOR DEVELOPER, LASER RECORDING NIPPON PAPER INDUSTRIES, CO., LTD. (JP) 1996-01-09 US disclosed
EP-0605149-A2 Recording sheet NIPPON PAPER INDUSTRIES CO., LTD. (JP) 1994-07-06 EP disclosed
EP-0158467-B1 METHOD FOR SELECTIVE METHYLATION OF ERYTHROMYCIN A DERIVATIVES TAISHO PHARMACEUTICAL CO. LTD (JP) 1989-07-05 EP disclosed
US-4672109-A Method for selective methylation of erythromycin A derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 1987-06-09 US disclosed
EP-0158467-A2 Method for selective methylation of erythromycin a derivatives TAISHO PHARMACEUTICAL CO. LTD (JP) 1985-10-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11987590-B2 Compounds that participate in cooperative binding and uses thereof CEP170, PIN1, FKBP3 ALDH1A1 4800/4885TSHR 4480/4885CYP3A4 2870/4885
US-20240165267-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 ALDH1A1 1969/4885TSHR 2428/4885CYP3A4 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.